Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26090735 | 1.00 | LMNA (0.43) | LMNAKDM1AGPBAR1OPRL1DRD2 | |
| SCHEMBL26092275 | 0.91 | LMNA (0.46) | LMNAGPBAR1OPRL1DRD2DRD4 | |
| SCHEMBL30379061 | 0.91 | LMNA (0.46) | LMNAGPBAR1OPRL1DRD2DRD4 | |
| SCHEMBL30910065 | 0.91 | LMNA (0.46) | LMNAGPBAR1OPRL1DRD2DRD4 | |
| SCHEMBL26091739 | 0.91 | LMNA (0.46) | LMNAGPBAR1OPRL1DRD2DRD4 | |
| SCHEMBL26087873 | 0.87 | DRD2 (0.44) | LMNAGPBAR1OPRL1DRD2DRD4 | |
| SCHEMBL30378636 | 0.87 | DRD2 (0.44) | LMNAGPBAR1OPRL1DRD2DRD4 | |
| SCHEMBL26089828 | 0.81 | LMNA (0.47) | LMNAGPBAR1TP53MAPT | |
| SCHEMBL30378966 | 0.81 | LMNA (0.47) | LMNAGPBAR1TP53MAPT | |
| SCHEMBL30379057 | 0.79 | CHRM2 (0.44) | LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SAPIENSBIO INC. (KR) | 2025-01-02 | — | — | US | claimed |
| EP-4421070-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sapiensbio Inc. (KR) | 2024-08-28 | — | — | EP | claimed |
| CN-118119612-A | Novel compounds and pharmaceutical compositions comprising the same | 萨皮恩斯生物有限公司 | 2024-05-31 | — | — | CN | claimed |
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SAPIENSBIO INC. (KR) | 2025-01-02 | — | — | US | disclosed |
| EP-4421070-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sapiensbio Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| CN-118119612-A | Novel compounds and pharmaceutical compositions comprising the same | 萨皮恩斯生物有限公司 | 2024-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | RHOA, ACTR2, MFAP1 | LMNA 1071/4885KDM1A 1774/4885GPBAR1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.